Insulin Isophane 50% + Human insulin 50%

Insulin isophane 50% + human insulin 50% is a premixed human insulin formulation used to improve blood glucose control in people with diabetes mellitus who require insulin treatment. It contains equal proportions of intermediate-acting insulin isophane, also known as NPH insulin, and short-acting soluble human insulin. Soluble human insulin begins lowering blood glucose relatively quickly and helps manage the rise that occurs after meals. Insulin isophane contains protamine, which slows insulin absorption and provides a longer period of glucose-lowering activity. Both components act on insulin receptors, promoting glucose uptake by muscle and fat cells and reducing glucose production by the liver. The combination is generally supplied as a suspension for subcutaneous injection. Its two components provide both mealtime and intermediate-duration insulin activity in one preparation. It may be suitable for selected people with type 1 or type 2 diabetes, depending on their treatment requirements and the product’s approved indications. Because the proportions are fixed, the short-acting and intermediate-acting components cannot be adjusted independently. Treatment therefore requires an appropriate meal routine, individualized dosing, regular blood glucose monitoring, and education about hypoglycaemia. The exact concentration, injection timing, preparation instructions, and approved uses must be confirmed from the specific product information.

Human insulin was developed as a replacement for the insulin naturally produced by the pancreas, and recombinant DNA technology enabled large-scale production of human insulin using genetically modified microorganisms. Premixed formulations combine soluble human insulin with insulin isophane to provide different durations of glucose-lowering activity in a single injection. The 50:50 formulation has been marketed in products such as Humulin 50/50 in the United States and Actraphane 50 in certain European markets, although product availability and authorization vary by country. The U.S. Food and Drug Administration has published prescribing information for Humulin 50/50, while the European Medicines Agency has assessed Actraphane products containing different ratios of soluble and isophane human insulin. Clinical studies of premixed human insulin formulations have evaluated blood glucose control and safety in people with diabetes. Approval dates, age indications, concentrations, and current market status depend on the exact product and jurisdiction; the applicable national prescribing information should be consulted before prescribing or dispensing.

Insulin isophane 50% + human insulin 50% is used to improve blood glucose control in people with diabetes mellitus who require insulin therapy. Depending on the specific product authorization and clinical circumstances, it may be used in type 1 or type 2 diabetes. In type 1 diabetes, insulin replacement is essential, but a fixed-ratio premix may not meet every patient’s changing basal and mealtime requirements. In type 2 diabetes, it may be prescribed when non-insulin medicines or other treatment approaches do not provide adequate glucose control, or when a premixed insulin regimen is considered appropriate. The formulation combines short-acting insulin for meal-related glucose increases with intermediate-acting insulin for longer coverage. It is not intended to treat diabetic ketoacidosis or other acute metabolic emergencies. Suitability depends on meal regularity, glucose patterns, lifestyle, and whether the fixed ratio can adequately meet the patient’s insulin requirements.

Insulin isophane 50% + human insulin 50% is generally administered by subcutaneous injection into approved areas such as the abdomen, thigh, upper arm, or buttocks, with injection sites rotated regularly. The dose and frequency must be individualized according to blood glucose measurements, meal patterns, activity, previous insulin use, and clinical response. Depending on the product and prescribed regimen, injections may be given once or more often daily. Some formulations are administered approximately 30 minutes before a meal, but the exact timing must follow the specific product’s instructions. The suspension must be prepared as directed so that the insulin is evenly mixed before administration. It must not be injected intravenously or used in an insulin pump unless the exact product information explicitly permits such use. Patients should not change doses or stop treatment without professional guidance. Regular glucose monitoring and review are needed, particularly when meals, activity, health status, or other medicines change.

The most common side effect is hypoglycaemia, or low blood glucose, which may cause sweating, shaking, hunger, dizziness, headache, palpitations, or difficulty concentrating. Other possible effects include weight gain, injection-site redness or discomfort, itching, and changes in the fatty tissue beneath the skin, including lipohypertrophy or lipoatrophy. Temporary swelling may occur in some patients, particularly when insulin treatment is started or glucose control improves rapidly. The likelihood of side effects depends on the dose, meal timing, physical activity, kidney or liver function, and use of other glucose-lowering medicines. Patients should follow their glucose-monitoring plan, rotate injection sites, and discuss repeated low-glucose episodes or unexplained changes in glucose levels with their healthcare professional.

Severe hypoglycaemia can cause confusion, seizures, loss of consciousness, or life-threatening complications and requires urgent treatment. Insulin can also lower blood potassium levels, potentially causing serious complications in susceptible patients. Rarely, serious allergic reactions may occur. Excessive dosing, delayed or missed meals, increased physical activity, illness, or changes in kidney or liver function may increase the risk of dangerously low or high blood glucose. Confusing insulin products, concentrations, or doses can result in serious medication errors. Because the formulation contains a fixed proportion of short-acting and intermediate-acting insulin, it may not be appropriate when these components need to be adjusted independently. It should not be used during an episode of hypoglycaemia, and it is not a treatment for diabetic ketoacidosis. Patients and caregivers should know how to recognize severe hypoglycaemia and when to seek emergency assistance. Any treatment interruption or dose change should be guided by a qualified healthcare professional.

Before treatment begins, clinicians should review the patient’s diabetes history, current medicines, glucose records, hypoglycaemia risk, eating schedule, physical activity, and kidney and liver function. Dose requirements may change during pregnancy, breastfeeding, acute illness, weight changes, or alterations in diet and activity. Other glucose-lowering medicines may increase the risk of hypoglycaemia when used with insulin. Corticosteroids, some diuretics, thyroid hormones, sympathomimetic medicines, and certain antipsychotics may alter glucose control and insulin requirements. Beta blockers can mask some warning signs of low blood glucose, while alcohol may increase or prolong the risk of hypoglycaemia. Patients should receive clear instructions about meal timing, injection technique, suspension preparation, storage, and management of missed meals. Insulin pens, cartridges, syringes, and needles should be used only as directed, and injection devices must never be shared. Monitoring and dose adjustment may be especially important in older adults and people with impaired renal or hepatic function.

Confirm the exact insulin formulation, the 50:50 ratio, concentration, device, and prescribed dose before dispensing or administration. Assess whether the patient’s meal schedule and glucose pattern are compatible with a fixed-ratio premixed insulin. Provide practical education on mixing the suspension correctly, injection timing, site rotation, glucose monitoring, and recognition and treatment of hypoglycaemia. Review glucose records before making dose changes and reassess treatment after changes in meals, physical activity, concurrent medicines, or kidney and liver function. Explain that the short-acting and intermediate-acting components cannot be independently titrated within the same injection. Pharmacists should verify the product-specific instructions and local authorization, demonstrate correct device use, and counsel patients on storage, expiry, safe disposal of needles, and prevention of insulin mix-ups. Ensure that patients have an individualized plan for low blood glucose and understand when urgent medical attention is required.